The cross-sectional GRAS sample: A comprehensive phenotypical data collection of schizophrenic patients

BMC Psychiatry

Research Article

Frank Löhrer¹  Jens Frahm²  Walter Stühmer³  Nils Brose⁴  Klaus-Armin Nave⁵  Thomas Becker⁶  Lothar Adler⁷  Adelheid Czernik⁸  Thomas Pollmächer⁹  Udo Schneider^1,10  Matthias Dose^1,11  Cornelia Oestereich^1,12  Here Folkerts^1,13  Wolfgang Maier^1,14  Ursula Havemann-Reinecke^1,15  Peter Falkai^1,16  Sabine Herpertz^1,17  Marlene Flögel^1,18  Annika Treitz^1,18  Anne Kästner^1,18  Martin F Gerchen^1,18  Verena Ackermann^1,18  Katja Ribbe^1,18  Sabrina Grube^1,18  Heidi Friedrichs^1,18  Asieh Tarami^1,18  Martin Begemann^1,18  Sergi Papiol^1,19  Hannelore Ehrenreich^2,20  Frank-Gerald Pajonk^2,21  Birgit Kröner-Herwig^2,22  Dirk Hesse^2,23  Gunther Kruse^2,24  Josef B Aldenhoff^2,25  Hans-Joachim Schwarz^2,26  Marianne Becker-Emner^2,27  Rüdiger Müller-Isberner^2,28  Roland Freese^2,29  Andreas Mielke^3,30  Rolf Günther^3,31  Heinrich Kunze^3,32  Michael Franz^3,32 

[1] Addiction Hospital "Am Waldsee", Rieden, Germany;Biomedical NMR Research GmbH, Max Planck Institute of Biophysical Chemistry, Göttingen, Germany;DFG Research Center for Molecular Physiology of the Brain (CMPB), Germany;Founders of the GRAS Initiative, India;Department of Molecular Biology of Neuronal Signals, Max Planck Institute of Experimental Medicine, Göttingen, Germany;DFG Research Center for Molecular Physiology of the Brain (CMPB), Germany;Founders of the GRAS Initiative, India;Department of Molecular Neurobiology, Max Planck Institute of Experimental Medicine, Göttingen, Germany;DFG Research Center for Molecular Physiology of the Brain (CMPB), Germany;Founders of the GRAS Initiative, India;Department of Neurogenetics, Max Planck Institute of Experimental Medicine, Göttingen, Germany;DFG Research Center for Molecular Physiology of the Brain (CMPB), Germany;Founders of the GRAS Initiative, India;Department of Psychiatry II, Ulm University, District Hospital Günzburg, Germany;Department of Psychiatry and Psychotherapy, Ecumenical Hospital Hainich, Germany;Department of Psychiatry and Psychotherapy, Hospital Fulda, Germany;Department of Psychiatry and Psychotherapy, Hospital Ingolstadt, Germany;Department of Psychiatry and Psychotherapy, Hospital Lübbecke, Germany;Department of Psychiatry and Psychotherapy, Isar-Amper-Hospital, Taufkirchen, (Vils), Germany;Department of Psychiatry and Psychotherapy, Regional Hospitals Hannover, Wunstorf, Germany;Department of Psychiatry and Psychotherapy, Reinhard-Nieter Hospital, Wilhelmshaven, Germany;Department of Psychiatry and Psychotherapy, University Medical Center of Bonn, Germany;Department of Psychiatry and Psychotherapy, University Medical Center of Göttingen, Germany;DFG Research Center for Molecular Physiology of the Brain (CMPB), Germany;Department of Psychiatry and Psychotherapy, University Medical Center of Göttingen, Germany;DFG Research Center for Molecular Physiology of the Brain (CMPB), Germany;Founders of the GRAS Initiative, India;Department of Psychiatry and Psychotherapy, University of Rostock, Germany;Division of Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Germany;Division of Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Germany;DFG Research Center for Molecular Physiology of the Brain (CMPB), Germany;Division of Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Germany;DFG Research Center for Molecular Physiology of the Brain (CMPB), Germany;Founders of the GRAS Initiative, India;Dr. K. Fontheim's Hospital for Mental Health, Liebenburg, Germany;Georg-Elias-Müller-Institute for Psychology, University of Göttingen, Germany;Hospital of Forensic Psychiatry, Moringen, Germany;Hospital of Psychiatry and Psychotherapy Langenhagen, Regional Hospitals Hannover, Germany;Hospital of Psychiatry and Psychotherapy, Center for Integrative Psychiatry, Kiel, Germany;Hospital of Psychiatry and Psychotherapy, Rickling, Germany;Karl-Jaspers-Hospital, Psychiatric Federation Oldenburger Land, Bad Zwischenahn, Germany;Vitos Haina Forensic Psychiatric Hospital, Haina, Germany;Vitos Hospital of Forensic Psychiatry Eltville, Eltville, Germany;Vitos Hospital of Psychiatry and Psychotherapy Merxhausen, Hofgeismar, Germany;Vitos Hospital of Psychiatry and Psychotherapy Merxhausen, Kassel, Germany;Vitos Hospital of Psychiatry and Psychotherapy, Bad Emstal-Merxhausen, Germany;

关键词: Schizophrenia;    Negative Symptom;    Schizophrenic Patient;    Antipsychotic Medication;    Divided Attention;   

DOI  :  10.1186/1471-244X-10-91

 received in 2010-08-24, accepted in 2010-11-10,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundSchizophrenia is the collective term for an exclusively clinically diagnosed, heterogeneous group of mental disorders with still obscure biological roots. Based on the assumption that valuable information about relevant genetic and environmental disease mechanisms can be obtained by association studies on patient cohorts of ≥ 1000 patients, if performed on detailed clinical datasets and quantifiable biological readouts, we generated a new schizophrenia data base, the GRAS (Göttingen Research Association for Schizophrenia) data collection. GRAS is the necessary ground to study genetic causes of the schizophrenic phenotype in a 'phenotype-based genetic association study' (PGAS). This approach is different from and complementary to the genome-wide association studies (GWAS) on schizophrenia.MethodsFor this purpose, 1085 patients were recruited between 2005 and 2010 by an invariable team of traveling investigators in a cross-sectional field study that comprised 23 German psychiatric hospitals. Additionally, chart records and discharge letters of all patients were collected.ResultsThe corresponding dataset extracted and presented in form of an overview here, comprises biographic information, disease history, medication including side effects, and results of comprehensive cross-sectional psychopathological, neuropsychological, and neurological examinations. With >3000 data points per schizophrenic subject, this data base of living patients, who are also accessible for follow-up studies, provides a wide-ranging and standardized phenotype characterization of as yet unprecedented detail.ConclusionsThe GRAS data base will serve as prerequisite for PGAS, a novel approach to better understanding 'the schizophrenias' through exploring the contribution of genetic variation to the schizophrenic phenotypes.

【 授权许可】

Unknown   
© Ribbe et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.